Aurobindo Pharma Patent-Cliff Exposure & CMS Drug Spending Portfolio
Aurobindo Pharma (East Windsor, NJ): 44 reconciled FDA prescription therapies (0.2% 2025 to 2030 cliff risk), $746.5M 2024 CMS Part D & Medicaid spend, and 9 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | East Windsor, NJ |
| Reconciled FDA Portfolio Therapies | 44 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 0.2% |
| Primary Portfolio LOE Date | 2027-01-01 |
| 2024 CMS Total Public Spend | $746.5M |
| 2024 Medicare Part D Spend | $507.2M |
| 2024 Medicaid Spend | $239.3M |
| California HCAI SB 17 Filings | 9 WAC filings (max 736.5% 2-yr change) |